AbbVie Inc. (ABBV): Price and Financial Metrics
AbbVie Inc. (ABBV)
Today's Latest Price: $92.92 USD
Updated Aug 7 12:00am
Add ABBV to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ABBV Stock Summary
- With a market capitalization of $163,988,305,218, AbbVie Inc has a greater market value than 99.08% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -42.76 for AbbVie Inc; that's greater than it is for just 0.61% of US stocks.
- In terms of volatility of its share price, ABBV is more volatile than just 4.46% of stocks we're observing.
- Stocks that are quantitatively similar to ABBV, based on their financial statements, market capitalization, and price volatility, are AMGN, ASX, GLW, TXN, and ITRI.
- Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to www.abbvie.com.
ABBV Stock Price Chart Technical Analysis Charts
ABBV Price/Volume Stats
| Current price | $92.92 | 52-week high | $101.28 |
| Prev. close | $92.57 | 52-week low | $62.55 |
| Day low | $92.20 | Volume | 5,227,000 |
| Day high | $93.00 | Avg. volume | 10,561,658 |
| 50-day MA | $96.18 | Dividend yield | 5.08% |
| 200-day MA | $87.89 | Market Cap | 163.99B |
AbbVie Inc. (ABBV) Company Bio
Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.
ABBV Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $92.92 | $242.43 | 160% |
We started the process of determining a valid price forecast for AbbVie Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that AbbVie Inc ranked in the 67th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 161.33%. The most interesting components of our discounted cash flow analysis for AbbVie Inc ended up being:
- The company's balance sheet shows it gets 64% of its capital from equity, and 36% of its capital from debt. Notably, its equity weight is greater than only 18.86% of US equities in the Healthcare sector yielding a positive free cash flow.
- AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 7.31% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 155% |
| 1% | 157% |
| 2% | 160% |
| 3% | 163% |
| 4% | 165% |
| 5% | 168% |
NVO, DVA, PCRX, LXRX, and EGRX can be thought of as valuation peers to ABBV, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...